Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Biliary Tract Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Cholangiocarcinoma (181
)
Gallbladder Cancer (41
)
Cholangiocarcinoma (181
)
Gallbladder Cancer (41
)
›
Associations
(321)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
Cholangiocarcinoma
HER-2 positive
Cholangiocarcinoma
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 3 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 3d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 3 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 3 days - (New C3)
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 6 days (New B)
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 6d
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 6 days
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 6 days - (New B)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 1wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week
futibatinib
Sensitive
:
A1
N Engl J Med - 1 week - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 1wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 1 week
futibatinib
Sensitive
:
A1
N Engl J Med - 1 week - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 1 week (New C4)
palbociclib
Sensitive
:
C4
Onco Targets Ther - 1wk
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 1 week
palbociclib
Sensitive
:
C4
Onco Targets Ther - 1 week - (New C4)
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 1 week (New C4)
capmatinib
Sensitive
:
C4
The Oncologist - 1wk
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 1 week
capmatinib
Sensitive
:
C4
The Oncologist - 1 week - (New C4)
PD-L1 expression
Biliary Tract Cancer
PD-L1 expression
Biliary Tract Cancer
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Cholangiocarcinoma
MDM2 amplification
Cholangiocarcinoma
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Biliary Tract Cancer
MDM2 amplification
Biliary Tract Cancer
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion
Cholangiocarcinoma
FGFR fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
KRAS mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification
Biliary Tract Cancer
HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
pemigatinib
Sensitive: A1 - Approval
pemigatinib
Sensitive
:
A1
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
GEM-CAP
Sensitive: A2 - Guideline
GEM-CAP
Sensitive
:
A2
GEM-CAP
Sensitive: A2 - Guideline
GEM-CAP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
XP
Sensitive: A2 - Guideline
XP
Sensitive
:
A2
XP
Sensitive: A2 - Guideline
XP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
XP
Sensitive: A2 - Guideline
XP
Sensitive
:
A2
XP
Sensitive: A2 - Guideline
XP
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
BRAF V600E
Biliary Tract Cancer
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
NTRK3 fusion
Biliary Tract Cancer
NTRK3 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Biliary Tract Cancer
NTRK2 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Biliary Tract Cancer
NTRK3 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Biliary Tract Cancer
NTRK2 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login